Drugs / Trastuzumab Emtansine (T-DM1)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05323955 Background | Mar 2023 → Nov 2026 expected | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Carey Anders, M.D. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzumab Emtansine (T-DM1) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05323955 ↗ |